Study of SARS-CoV2 Virus (COVID-19) Seroprevalence Among Lyon-Bron Military Health Schools Personnel
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- SARS-CoV Infection
- Sponsor
- Direction Centrale du Service de Santé des Armées
- Enrollment
- 392
- Locations
- 1
- Primary Endpoint
- Proportion of anti-SARS-CoV2 seropositive participants
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
Emerging in China in December 2019, Covid-19, whose pathogen is SARS-Cov-2, was declared a global pandemic in March 2020. The clinical presentation is highly variable, ranging from asymptomatic forms to acute respiratory distress and even death. Transmission is by droplet route, with an R0 of approximately 3.
Rapidly, population protection measures were put in place by governments, including the confinement of all persons whose functions were not considered essential and the closure of educational institutions.
Health care institutions are places at risk of Covid-19 transmission and hospital staff are particularly exposed, either through direct contact with patients, contact with exposed persons or through the environment. In order to protect personnel, hygiene measures were immediately recalled and reinforced.
During the period of containment, the majority of students from the Lyon-Bron Military Medical Schools were sent as reinforcement in Army Training Hospitals and in the Military Reanimation Unit (Mulhouse). Some students developed symptomatic forms of SARS-Cov-2 infection, documented by positive PCR, during Operation Resilience or on their return from the mission.
The Lyon-Bron Military Medical Schools staff, exposed both to the initial phase of the epidemic and to national protection measures, represent an extremely interesting population for understanding the epidemiological dynamics of the virus.
Investigators
Eligibility Criteria
Inclusion Criteria
- •at least 18 years of age
- •personnel of the Military Health Schools of Lyon-Bron
- •working at the Military Health Schools of Lyon-Bron during the COVID-19 crisis
Exclusion Criteria
- •contraindication to blood sampling
Outcomes
Primary Outcomes
Proportion of anti-SARS-CoV2 seropositive participants
Time Frame: Day 0
The proportion of anti-SARS-CoV2 seropositive participants will be determined. ELISA serology test will be used to detect anti-SARS-CoV2 antibodies (IgG and IgM) at Day 0.
Secondary Outcomes
- Proportion of asymptomatic participants (among anti-SARS-CoV2 seropositive participants)(Day 0)
- Correlation coefficient between social risk factors and a positive serology(Day 0)
- Correlation coefficient between medical risk factors and a positive serology(Day 0)
- Correlation coefficient between epidemiological risk factors and a positive serology(Day 0)